Page last updated: 2024-09-05

sb 203580 and isoxazoles

sb 203580 has been researched along with isoxazoles in 1 studies

Compound Research Comparison

Studies (sb 203580)	Trials (sb 203580)	Recent Studies (post-2010) (sb 203580)	Studies (isoxazoles)	Trials (isoxazoles)	Recent Studies (post-2010) (isoxazoles)
3,489	4	1,137	8,633	900	3,337

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bussink, J; Grénman, R; Iida, M; Kaanders, JH; Peeters, WJ; Span, PN; Stegeman, H; van der Kogel, AJ; Verheijen, MM; Wheeler, DL	1

Other Studies

1 other study(ies) available for sb 203580 and isoxazoles

Article	Year
Combining radiotherapy with MEK1/2, STAT5 or STAT6 inhibition reduces survival of head and neck cancer lines. Molecular cancer, 2013, Nov-05, Volume: 12, Issue:1 Topics: Antineoplastic Agents; Butadienes; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Chemoradiotherapy; Dasatinib; Drug Screening Assays, Antitumor; Head and Neck Neoplasms; Humans; Imidazoles; Isoxazoles; Leflunomide; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Nitriles; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Radiation Tolerance; STAT5 Transcription Factor; STAT6 Transcription Factor; Thiazoles; Tumor Suppressor Proteins	2013

Article

Year

Combining radiotherapy with MEK1/2, STAT5 or STAT6 inhibition reduces survival of head and neck cancer lines.

Molecular cancer, 2013, Nov-05, Volume: 12, Issue:1

Topics: Antineoplastic Agents; Butadienes; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Chemoradiotherapy; Dasatinib; Drug Screening Assays, Antitumor; Head and Neck Neoplasms; Humans; Imidazoles; Isoxazoles; Leflunomide; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Nitriles; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Radiation Tolerance; STAT5 Transcription Factor; STAT6 Transcription Factor; Thiazoles; Tumor Suppressor Proteins

2013